Skip to main content
. Author manuscript; available in PMC: 2023 Mar 28.
Published in final edited form as: N Engl J Med. 2019 May 30;380(22):2104–2115. doi: 10.1056/NEJMoa1817249

Figure 1. Progression-free Survival.

Figure 1.

Shown are the results of the Kaplan–Meier estimates of progression-free survival among patients in the intention-to-treat population. The daratumumab group received treatment with daratumumab, lenalidomide, and dexamethasone; the control group received treatment with lenalidomide and dexamethasone. The interim analysis of progression-free survival was performed after 240 events of disease progression or death had occurred (62% of the planned 390 events for the final analysis).